D&O Ongoing Disclosure Notices

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
21 September 2018
Date of last disclosure:
28 June 2018
Director or senior manager giving disclosure
Full name(s):
Michael Grenfell Daniell
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Performance Share Rights
(b) Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest:
Number held in class before acquisition or disposal:
(a) 30,000 Performance Share Rights
(b) 970,927 Ordinary Shares
Number held in class after acquisition or disposal:
(a) 0 Performance Share Rights
(b) 970,927 Ordinary Shares
Current registered holder(s):
Michael Grenfell Daniell and Daniell Family Trust
Registered holder(s) once transfers are registered:
Michael Grenfell Daniell and Daniell Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure:
Date of transaction:
(a) 17 September 2018
(b) 18 September 2018

Nature of transaction:
(a) Exercise of 30,000 Performance Share Rights
and issue of 30,000 Ordinary Shares
(b) Sale of 30,000 Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
(a) $452,700
(b) $453,750
Number of financial products to which the transaction related:
(a) 30,000 Peformance Share Rights and 30,000
Ordinary Shares
(b) 30,000 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details:
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Options to acquire Ordinary Shares
Nature of relevant interest:
Beneficial Interest
For that relevant interest:
Number held in class:
80,000 Options to acquire Ordinary Shares
Current registered holder(s):
Michael Grenfell Daniell
For a derivative relevant interest:
Type of derivative:
Details of derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
21 September 2018
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
21 September 2018
Date of last disclosure:
03 September 2018
Director or senior manager giving disclosure
Full name(s):
Antony George BARCLAY
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Former Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
(a) Performance Shares Rights
(b) Options to acquire Ordinary Shares
(c) Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial Interest
For that relevant interest-
Number held in class before acquisition or disposal:
(a) 34,740 Performance Shares Rights
(b) 99,106 Options to acquire Ordinary Shares
(c) 126,985 Ordinary Shares
Number held in class after acquisition or disposal:
(a) 20,240 Performance Shares Rights
(b) 79,106 Options to acquire Ordinary Shares
(c) 151,929 Ordinary Shares
Current registered holder(s):
Antony George BARCLAY
Registered holder(s) once transfers are registered:
Antony George BARCLAY
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
Date of transaction:
(a) 12 September 2018
(b) 18 September 2018

Nature of transaction:
(a) Exercise of 14,500 Performance Share Rights and issue
of 14,500 Ordinary Shares
(b) Exercise of 20,000 Options and issue of 10,444
Ordinary Shares
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
(a) $218,950
(b) $160,002
Number of financial products to which the transaction related:
(a) 14,500 Performance Share Rights and 14,500 Ordinary
Shares
(b) 20,000 Options to acquire Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):Antony George BARCLAY
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
21 September 2018
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes